Economic analysis of randomized, controlled trials
To facilitate the comparison of different treatment strategies, measures have been developed that bring together clinical, quality-of-life, and economic outcomes into summary measures such as the quality-adjusted life year, cost-effectiveness, and cost-utility ratios. A number of different types of economic evaluations have been developed, including cost-minimization, cost-effectiveness, and cost-utility analyses. Performance of economic analyses in association with randomized, controlled trials (RCT) has gained increasing enthusiasm in recent years. However, economic measures in RCTs are often outcomes of secondary interest and associated with frequent missing data and inadequate sample size. Variability in the cost measures used and the lack of agreement on clinically meaningful cost differences further limit the conclusions derived from such studies. Economic analyses should be limited to large trials with important trade-offs between efficacy and cost. The strengths and limitations of such analyses are discussed, and guidelines are offered for proper economic analyses in randomized, controlled trials.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Brown ML, Fintor L: The economic burden of cancer. In Cancer Prevention and Control. Edited by Greenwald P, Kramer BS, Weed, DC. New York: Marcel Dekker; 1995:1–12.Google Scholar
- 3.Gaumer GL, Stavins J: Medicare use in the last 90 days of life. Med Care 1991, 29:725–742.Google Scholar
- 4.Baker MS, Kessler LC: Site-specific treatment costs In. In Cancer Care and Cost. Edited by Scheffler RM, Andews NC. Chicago: Health Administration Press; 1989.Google Scholar
- 8.Gelber RD, Goldhirsch A, Cavelli F: Quality-of-life-adjusted evaluation of adjuvant therapy for operable breast cancer. Ann Int Med 1991, 114:621–628. This important paper addresses the cumulative impact of patient preferences over time, expressed as quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST), enhancing the power to demonstrate an impact of treatment on patient quality of life.PubMedGoogle Scholar
- 11.Staquet MJ, Hays RD, Fayers PM: Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press; 1998.Google Scholar
- 16.Task Force on Principles for Economic Analyses of Health Care Technology: Economic analyses of health care technology: a report on principles. Ann Int Med 1995, 122:61–70.Google Scholar
- 17.American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996, 14:671–679.Google Scholar
- 20.Siegel JE, Weinstein MC, Russell LB, Gold MR: Recommendations for reporting cost-effectiveness analysis. JAMA 1996, 276:1330–1341. Landmark companion papers representing a comprehensive effort to define the role of economic analysis in health care and provide guidelines for the conduct and reporting of such analyses in the medical literature.CrossRefGoogle Scholar
- 23.Drummond MF, Stoddart GL: Economic analysis and clinical trials. Controlled Clinical Trials 1984, 5:115–128. A pivotal paper by one of the pioneers and leading authorities in defining the role of economic analyses in association with controlled clinical trials. Most of the major strengths and weaknesses associated with such studies are discussed.PubMedCrossRefGoogle Scholar
- 27.Brown M, Glick HA, Harrell F, et al.: Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology economics workbook. J Natl Cancer Inst Monogr 1998, 24:1–28. Excellent overview of the second national conference on the design and analysis of economic analyses in association with controlled clinical trials. Participants included clinicians, statisticians, and economists as well as representatives of the major national cancer cooperative groups, the National Cancer Institute, and the American Society of Clinical Oncology.Google Scholar
- 40.Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993, 85:1460–1474. Comprehensive compilation of efficacy and cost-effectiveness studies in oncology based on decision analysis methods.PubMedCrossRefGoogle Scholar